Allan J. Barnes

发表

Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration

M. Huestis, R. Vandrey, Ryan Vandrey, 2013, Analytical and Bioanalytical Chemistry.

Performance characteristics of the Cozart RapiScan Oral Fluid Drug Testing System for opiates in comparison to ELISA and GC/MS following controlled codeine administration.

M. Huestis, C. Reid, Insook Kim, 2004, Forensic science international.

Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration.

M. Huestis, E. Cone, Insook Kim, 2002, Clinical chemistry.

Disposition of cocaine and its metabolites in human sweat after controlled cocaine administration.

M. Huestis, E. Cone, E. Moolchan, 2005, Clinical chemistry.

Sensitivity, specificity, and efficiency in detecting opiates in oral fluid with the Cozart Opiate Microplate EIA and GC-MS following controlled codeine administration.

M. Huestis, C. Reid, Insook Kim, 2003, Journal of analytical toxicology.

Recent Self-Reported Cannabis Use Is Associated With the Biometrics of Delta-9-Tetrahydrocannabinol.

H. Breiter, M. Huestis, Eva C. Alden, 2018, Journal of studies on alcohol and drugs.

Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry.

M. Huestis, K. Scheidweiler, Allan J. Barnes, 2016, Journal of chromatography. A.

Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.

J. Hirvonen, M. Huestis, Allan J. Barnes, 2011, Clinical chemistry.

Validation of a two-dimensional gas chromatography mass spectrometry method for the simultaneous quantification of cannabidiol, Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in plasma

M. Huestis, K. Scheidweiler, Allan J. Barnes, 2010, Analytical and bioanalytical chemistry.

Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers

M. Huestis, G. Galloway, M. Baggott, 2019, Journal of psychoactive drugs.

Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.

O. Abulseoud, M. Huestis, K. Scheidweiler, 2016, Clinical chemistry.

CLINICAL STUDY: Postmortem diagnosis and toxicological validation of illicit substance use

J. Kleinman, J. Cadet, W. Freed, 2008, Addiction biology.

Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.

M. Huestis, R. Vandrey, Allan J. Barnes, 2015, Journal of analytical toxicology.

Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol and 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol in Human Plasma After Controlled Oral Administration of Cannabinoids

Richard A. Gustafson, M. Huestis, E. Moolchan, 2006 .

Quantification of Eight Cannabinoids Including Cannabidiol in Human Urine Via Liquid Chromatography Tandem Mass Spectrometry.

K. Scheidweiler, Allan J. Barnes, 2018, Methods in molecular biology.

Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers.

Nathalie A. Desrosiers, M. Huestis, D. Gorelick, 2014, Drug testing and analysis.

Plasma Cannabinoid Concentrations During Dronabinol Pharmacotherapy for Cannabis Dependence

M. Huestis, R. Vandrey, Allan J. Barnes, 2014, Therapeutic drug monitoring.

Simultaneous quantification of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry.

M. Huestis, Allan J. Barnes, Ross H. Lowe, 2007, Journal of chromatography. A.

Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections.

M. Huestis, Allan J. Barnes, Michael L. Smith, 2009, Journal of analytical toxicology.

Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat.

M. Huestis, B. D. de Martinis, K. Scheidweiler, 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?

M. Huestis, Allan J. Barnes, G. Milman, 2013, Drug and alcohol dependence.

Evaluation of a homogenous enzyme immunoassay for the detection of synthetic cannabinoids in urine.

T. M. Martin, K. Klette, M. Huestis, 2014, Forensic science international.

Optimization of recombinant β-glucuronidase hydrolysis and quantification of eight urinary cannabinoids and metabolites by liquid chromatography tandem mass spectrometry.

M. Huestis, K. Scheidweiler, Allan J. Barnes, 2018, Drug testing and analysis.

The acute effect of cannabis on plasma, liver and brain ammonia dynamics, a translational study

O. Abulseoud, M. Huestis, Lifeng Zhang, 2017, European Neuropsychopharmacology.

Development and validation of a solid-phase extraction gas chromatography–mass spectrometry method for the simultaneous quantification of methadone, heroin, cocaine and metabolites in sweat

M. Huestis, K. Scheidweiler, Allan J. Barnes, 2008, Analytical and bioanalytical chemistry.

Maternal Buprenorphine Maintenance and Lactation

H. Jones, M. Huestis, K. Scheidweiler, 2016, Journal of human lactation : official journal of International Lactation Consultant Association.

Effect of hydrolysis on identifying prenatal cannabis exposure

M. Huestis, Allan J. Barnes, Teresa R. Gray, 2010, Analytical and bioanalytical chemistry.

3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration

Nathalie A. Desrosiers, M. Huestis, D. Gorelick, 2013, Analytical and Bioanalytical Chemistry.

Simultaneous quantification of 11 cannabinoids and metabolites in human urine by liquid chromatography tandem mass spectrometry using WAX-S tips

M. Huestis, K. Scheidweiler, Allan J. Barnes, 2016, Analytical and Bioanalytical Chemistry.

Opioid disposition in human sweat after controlled oral codeine administration.

M. Huestis, E. Cone, E. Moolchan, 2006, Clinical chemistry.

Simultaneous quantification of methamphetamine, cocaine, codeine, and metabolites in skin by positive chemical ionization gas chromatography-mass spectrometry.

M. Ripple, M. Huestis, E. Cone, 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Cocaine and metabolite concentrations in DBS and venous blood after controlled intravenous cocaine administration.

Kayla N. Ellefsen, Sébastien Anizan, M. Huestis, 2015, Bioanalysis.

Cannabinoid concentrations in hair from documented cannabis users.

Richard A. Gustafson, M. Huestis, E. Moolchan, 2007, Forensic science international.

Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry.

M. Huestis, Allan J. Barnes, G. Milman, 2010, Journal of chromatography. A.

Impact of oral fluid collection device on cannabinoid stability following smoked cannabis.

Sébastien Anizan, Nathalie A. Desrosiers, M. Huestis, 2015, Drug testing and analysis.

Cannabinoid stability in authentic oral fluid after controlled cannabis smoking.

M. Huestis, D. Gorelick, Allan J. Barnes, 2012, Clinical chemistry.

Cannabinoid disposition in oral fluid after controlled smoked cannabis.

M. Huestis, D. Gorelick, Allan J Barnes, 2012, Clinical chemistry.

Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration.

Marilyn A Huestis, Edward J Cone, M. Huestis, 2006, Journal of analytical toxicology.

Urine Mescaline Screening With a Biochip Array Immunoassay and Quantification by Gas Chromatography–Mass Spectrometry

M. Castaneto, T. M. Martin, K. Klette, 2015, Therapeutic drug monitoring.

Cozart RapiScan Oral Fluid Drug Testing System: an evaluation of sensitivity, specificity, and efficiency for cocaine detection compared with ELISA and GC-MS following controlled cocaine administration.

M. Huestis, C. Reid, Insook Kim, 2003, Journal of analytical toxicology.

Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine

Y. Hurd, M. Huestis, Allan J. Barnes, 2013, Analytical and Bioanalytical Chemistry.

Simultaneous quantification of buprenorphine, naloxone and phase I and II metabolites in plasma and breastmilk by liquid chromatography-tandem mass spectrometry.

M. Huestis, K. Scheidweiler, Allan J Barnes, 2016, Journal of chromatography. A.

Disposition of MDMA and metabolites in human sweat following controlled MDMA administration.

M. Huestis, D. Gorelick, B. D. de Martinis, 2009, Clinical chemistry.

A validated gas chromatographic-electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brain.

M. Huestis, K. Scheidweiler, Allan J Barnes, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.

Marilyn A Huestis, M. Huestis, D. Gorelick, 2009, Journal of analytical toxicology.

Identifying Methamphetamine Exposure in Children

M. Castaneto, M. Huestis, M. Schaffer, 2013, Therapeutic drug monitoring.

Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.

M. Huestis, E. Cone, E. Moolchan, 2008, Clinical chemistry.

A validated positive chemical ionization GC/MS method for the identification and quantification of amphetamine, opiates, cocaine, and metabolites in human postmortem brain.

J. Kleinman, W. Freed, T. Hyde, 2006, Journal of mass spectrometry : JMS.

Sensitivity and specificity of the Cozart microplate EIA cocaine oral fluid at proposed screening and confirmation cutoffs.

M. Huestis, C. Reid, Insook Kim, 2003, Clinical chemistry.

Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers

Sébastien Anizan, Nathalie A. Desrosiers, M. Huestis, 2013, Analytical and Bioanalytical Chemistry.

Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.

Sébastien Anizan, M. Huestis, R. Vandrey, 2013, Clinical chemistry.

On-site oral fluid Δ9-tetrahydrocannabinol (THC) screening after controlled smoked, vaporized, and oral cannabis administration

O. Abulseoud, M. Huestis, K. Scheidweiler, 2016, Forensic Toxicology.

Cannabinoids in oral fluid by on-site immunoassay and by GC-MS using two different oral fluid collection devices

Nathalie A. Desrosiers, M. Huestis, D. Gorelick, 2014, Analytical and Bioanalytical Chemistry.

On-site test for cannabinoids in oral fluid.

Nathalie A. Desrosiers, M. Huestis, D. Gorelick, 2012, Clinical chemistry.

Estimating Time of Last Oral Ingestion of Cannabis From Plasma THC and THCCOOH Concentrations

Richard A. Gustafson, M. Huestis, M. Elsohly, 2006, Therapeutic drug monitoring.

Excretion of Methadone in Sweat of Pregnant Women Throughout Gestation After Controlled Methadone Administration

H. Jones, M. Huestis, Rolley E. Johnson, 2010, Therapeutic drug monitoring.

Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

J. Rehm, M. Huestis, B. Le Foll, 2016, Drug and alcohol dependence.

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial

D. Streiner, J. Rehm, A. Soliman, 2018, PloS one.

Effects of fixed or self-titrated dosages of Sativex on cannabis users

J. Rehm, M. Huestis, B. Fischer, 2015 .

Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans

Y. Hurd, R. Sinha, M. Huestis, 2015, Journal of addiction medicine.

Validation of an ELISA Synthetic Cannabinoids Urine Assay

T. M. Martin, M. Huestis, Allan J. Barnes, 2015, Therapeutic drug monitoring.

Performance characteristics of an ELISA screening assay for urinary synthetic cannabinoids.

M. Castaneto, T. M. Martin, K. Klette, 2015, Drug testing and analysis.

Automated and semi-automated screening, LCMSMS confirmation and human hepatocyte high-resolution metabolism studies of synthetic cannabinoids

M. Castaneto, Nathalie A. Desrosiers, M. Huestis, 2013 .

Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.

D. Kelly, M. Huestis, D. Gorelick, 2010, Clinical chemistry.

Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series

A. Soliman, T. George, M. Huestis, 2016, Journal of addiction medicine.

Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration

Nathalie A. Desrosiers, M. Huestis, D. Gorelick, 2013, Analytical and Bioanalytical Chemistry.

A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis

B. Wilsey, T. Marcotte, M. Huestis, 2016, Journal of pain research.

Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.

M. Huestis, D. Mendu, R. Vandrey, 2015, Drug testing and analysis.

Pharmacokinetics of Cocaine and Metabolites in Human Oral Fluid and Correlation With Plasma Concentrations After Controlled Administration

M. Huestis, E. Cone, T. Kelly, 2010, Therapeutic drug monitoring.

Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration

M. Huestis, D. Gorelick, Allan J. Barnes, 2011, Analytical and bioanalytical chemistry.

Quantification of 11-Nor-9-Carboxy-&Dgr;9-Tetrahydrocannabinol in Human Oral Fluid by Gas Chromatography–Tandem Mass Spectrometry

M. Huestis, K. Scheidweiler, Allan J. Barnes, 2014, Therapeutic drug monitoring.

Biochip array technology immunoassay performance and quantitative confirmation of designer piperazines for urine workplace drug testing

M. Castaneto, K. Klette, M. Huestis, 2015, Analytical and Bioanalytical Chemistry.

Estimating the Time of Last Cannabis Use from Plasma Δ9-Tetrahydrocannabinol and 11-nor-9-Carboxy-Δ9-Tetrahydrocannabinol Concentrations

M. Huestis, Allan J. Barnes, Michael L. Smith, 2005 .

Validated method for the simultaneous determination of Delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC and 11-nor-9-carboxy-THC in human plasma using solid phase extraction and gas chromatography-mass spectrometry with positive chemical ionization.

Richard A. Gustafson, M. Huestis, E. Moolchan, 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.

M. Huestis, M. Meyer, D. Gorelick, 2011, Clinical chemistry.

Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.

M. Huestis, M. Meyer, D. Gorelick, 2012, Biochemical pharmacology.

Human MDMA (Ecstasy) and Phase I and Phase II Metabolite Urinary Excretion Kinetics Following Controlled MDMA Administration

M. Huestis, M. Meyer, D. Gorelick, 2011 .

(±)-3,4-methylenedioxymethamphetamine and metabolite disposition in plasma and striatum of wild-type and multidrug resistance protein 1a knock-out mice.

J. Cadet, M. Huestis, B. Ladenheim, 2011, Journal of analytical toxicology.

MDMA and Metabolite Disposition in Expectorated Oral Fluid After Controlled Oral MDMA Administration

M. Huestis, D. Gorelick, K. Scheidweiler, 2011, Therapeutic drug monitoring.

Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations.

M. Huestis, Allan J. Barnes, Michael L. Smith, 2005, Clinical Chemistry.

Monitoring Pregnant Women's Illicit Opiate and Cocaine Use With Sweat Testing

H. Jones, M. Huestis, Allan J. Barnes, 2010, Therapeutic drug monitoring.

Excretion of Methadone in Sweat of Pregnant Women Throughout Gestation After Controlled Methadone Administration

H. Jones, M. Huestis, Rolley E. Johnson, 2010, Therapeutic drug monitoring.

Postmortem diagnosis and toxicological validation of illicit substance use.

M. Huestis, E. Lehrmann, A. Deep-Soboslay, 2008, Addiction biology.

Cannabinoid stability in authentic oral fluid after controlled cannabis smoking.

M. Huestis, D. Gorelick, Allan J. Barnes, 2012, Clinical chemistry.